BioSpace News Archive

Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, will present at the SITC 37th Annual Meeting (2022) in Boston, MA.

AIM ImmunoTech Inc. announced the following corporate governance enhancements: The Governance and Nominating Committee of the AIM Board of Directors has initiated a process to add two directors who bring diversity and additional biotechnology commercialization experience to the Board.

ClearPoint Neuro, Inc., a global therapy-enabling platform company providing navigation and delivery to the brain, announced that its management will present at the following investor conferences.

Brandon Capital announces its participation in NRG Therapeutics’ £16 million (AUD$29m) Series A alongside Omega Funds

Minimally invasive image-guided treatment solution and technology company, SpinaFX Medical Inc. (SpinaFX), today announced the quality management system underlying its Triojection® system has been certified compliant with ISO 13485:2016/Medical Device Single Audit Program (MDSAP) for U.S. and Canada and EN ISO 13485:2016 for Europe.

According to Latest Report Study, the clinical trials market was estimated to be worth USD 51.05 billion in 2021 and is anticipated to grow to USD 84.43 billion by 2030, with a CAGR of 5.7% from 2022 to 2030.

Salt Lake City, Utah--(Newsfile Corp. - November 9, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) today is providing a business update and reporting financial results for the three and nine months ended September 30, 2022.

Avstera Therapeutics Corp., a biotechnology company based in the Philadelphia area, has announced the completion of its seed round to advance its lead cancer programs geared towards targeting solid tumors.

Therapeutic Solutions International (TSOI) announced today the launching of a spin-off company, Breathe Biologics, Inc., to commercialize technologies in the area of COPD.

Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced that its phase 2 clinical trial of RSLV-132 in patients with long covid has been fully enrolled (NCT04944121).